Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Equal-Weight and lowers the price target from $40 to $37.
Morgan Stanley Maintains Equal-Weight on Arrowhead Pharma, Lowers Price Target to $37
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.